Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Clar, Christine; Gill, James Alexander; Court, Rachel; Waugh, Norman
BMJ open; 2012;2(5) PMID: 23087012
Systematic review, Berlin, Germany.


Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends to be a progressive disease, and most patients require treatment with combinations of glucose-lowering agents. The sodium glucose co-transporter 2 (SGLT2) receptor inhibitors are a new class of glucose-lowering agents.